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Impact of FLT3 ITD/NPM1 mutation status in adult patients with acute myelocytic leukemia autografted in first remission
In patients with no chromosomal abnormalities (NC-AML) treated with chemotherapy, the detection of a FLT3-ITD and a mutation in NPM1 have helped in defining three risk categories, the worst corresponding to AML with an ITD and no were more likely to bear NPM1 mutation (59% vs 40%; p=0.03). Of these patients, 49% (100) were ITD-negative/NPM1-unmutated, 32.5% (66) were ITDnegative/NPM1-mutated, 11% (22) were ITD-positive/NPM1-mutated, and 7% (15) were ITD-positive/NPM1-unmutated.
The proportion of slow remitters (more than one induction chemotherapy course to achieve CR1) was higher in the group with an ITD (22% vs 11%; p=0.04).
The 3-year LFS rate of the whole population was 47 ± 3% .The RI was 47 ± 3%, and the NRM 6 ± 1%.
The Table shows the results of the univariate analyses.
Patients without a FLT3/ITD had a lower RI (42 ± 4% vs 58 ± 5%, p= 0.002) and a better LFS (52 ± 4% vs 34 ± 5%; p=0.001) and OS (66± 3% vs 47± 6% ; p= 0.0006) than those with an ITD. Patients younger than 50 years of age had a better LFS (54 ± 4% vs 39 ± 4%; p=0.04). Patients with good cytogenetics had the lowest RI (25 ± 7%) and the best LFS (70 ± 7%) compared to all other patients (RI: 50 ± 3%; p=0.003; LFS: 43 ± 3%; p= 0.009). Rapid remitters had a lower RI (42 ± 4% vs 65 ± 9%; p=0.001) and a better LFS (50 ± 4% vs 35 ± 9%; p= 0.01).
The figure shows LFS for the four groups of patients defined by the two molecular markers. ITD-positive/NPM1-unmutated patients had the worst LFS (23 ± 11%) and OS ( 37± 18% ) and the highest RI (70 ± 13%) compared to the other three groups.
Interestingly, in ITD-positive/NPM1-mutated patients, the LFS was 48± 13%, the OS 69± 13% , the RI 52 ± 14%, not different from the outcome of ITD-negative/NPM1-unmutated patients.
In multivariate analysis, both the presence of a FLT3/ITD and slow remitters were predictive of higher RI and lower LFS. 
